#Stemcells

Robert F. Kennedy Jr., now serving as US Secretary of Health and Human Services, has ignited international debate by vowing to dramatically expand access to experimental and alternative medical treatments in America. During a recent appearance on the “Ultimate Human” podcast, Kennedy announced his commitment to “end the war at the FDA against alternative medicine,” directly challenging longstanding regulatory practices around therapies ranging from stem cell treatments and chelation therapy to dietary supplements and hyperbaric oxygen therapy (Gizmodo, Yahoo News). While patient autonomy and the desire for broader therapeutic choices resonate with many, Kennedy’s stance has provoked fierce debate among medical professionals, regulators, and public health advocates—both in the US and abroad. For Thailand, where complementary, traditional, and alternative medicine (CAM) is interwoven into the fabric of national healthcare policy and cultural practice, Kennedy’s pronouncements serve as an opportunity for critical reflection about safety, evidence, and the role of regulation in health innovation.

A worldwide debate on alternative medicine has intensified after US Health Secretary Robert F. Kennedy Jr. signaled a major shift toward broader access to experimental and non-traditional therapies. On a recent podcast, Kennedy argued that regulators should “just do the science” and inform patients without unduly restricting physicians or choices, while acknowledging the risk of misinformation. The stance has sparked a wide-ranging discussion among medical experts, regulators, and public health advocates in Thailand, where complementary and traditional therapies are embedded in national health policy and daily practice.

A new study from the Institute of Science and Technology Austria (ISTA) introduces a brain organoid model that includes microglia, the brain’s immune cells. This addition enhances the model’s ability to simulate inflammation and improves prospects for safer pharmaceutical testing during pregnancy. The development is timely for global health and aligns with Thai prenatal care policy ambitions to refine safe medication guidelines for expectant mothers.

Historically, brain organoid models lacked microglia, limiting their accuracy in mimicking how the human brain responds to infections. By incorporating microglia, researchers can better understand how the developing nervous system reacts to infections such as Rubella, a concern for pregnant women due to potential fetal complications. In Thailand, where maternal and neonatal health remains a policy priority, this research supports national efforts to reduce congenital risks and strengthen prenatal care.